Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion type Assertion NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_head.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion description "[Furthermore, NAT2 slow-acetylator, GSTM1 null, and GSTM1/GSTT1-double null genotypes were associated with higher tumor grade (P=0.001, 0.022, and 0.036, respectively), and only NAT2 slow-acetylator genotype was associated with higher tumor stage (P=0.007).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_provenance.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion evidence source_evidence_literature NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_provenance.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion SIO_000772 19303722 NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_provenance.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion wasDerivedFrom befree-20150227 NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_provenance.
- NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_assertion wasGeneratedBy ECO_0000203 NP441046.RAXhErQckmE960lj4TWcBnSUfS4mYAKIHTa-zzeptNH14130_provenance.